Spotlight on Pediatrics
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 12: HIV and CVD
StartActivity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions
Activity Description
As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions
Activity Description
As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Pediatrics Presentations
No programs are available for this specialty. Check back later.